Following a study of some 2,261 men with metastatic prostate cancer (that had spread to the bones or lymph glands) researchers at University College London, funded by Prostate Cancer UK, have recommended that men with “low burden” advanced but smaller tumours, could be given hormone treatment alone, without any negative impact on their survival rates. Hence there would be no need for the men to have to face chemotherapy treatment.

Each year over 47,500 men are diagnosed with prostate cancer, of which around 6,000 will be metastatic. Prostate Cancer UK has said that the change to treatment pathways could start “straight way” although the NHS will need to consider this further before agreeing to implement changes.

Source: The Times, 18 June 2022.